Table 1 Overview of head to head comparisons amongst GLP-1 analogues and DPP-4 inhibitors.
From: Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
Study | Duration | Type | GLP-1 analogue | DPP-4 inhibitor | Co- existing therapy |
|---|---|---|---|---|---|
DeFronzo et al. [31] | 4 weeks | Double blind, double dummy, cross over | Exenatide 5 mcg twice daily for 1st week followed by 10 mcg twice daily for 2nd week | Sitagliptin 100 mg once daily | Metformin |
Berg et al. [32] | 8 weeks | Double blind, double dummy, cross over | Exenatide 10 mcg twice daily | Sitagliptin 100 mg once daily | none |
1860-Lira DPP4 [33] | 26 weeks | Open label parallel group | Liraglutide 1.2 mg and Liraglutide 1.8 mg | Sitagliptin 100 mg once daily | Metformin |
DURATION 2 [35] | 26 weeks | Double dummy | Exenatide QW 2 mg once weekly | Sitagliptin 100 mg once daily | Metformin |
DURATION 4 [37] | 26 weeks | Double dummy | Exenatide QW 2 mg once weekly | Sitagliptin 100 mg once daily | none |
T-emerge 4 [39] | 24 weeks | Double dummy | Taspoglutide 10 mg and 20 mg weekly | Sitagliptin 100 mg once daily | Metformin |
1860- Lira DPP4 extension [34] | 52 weeks | Open label parallel group | Exenatide 10 mcg twice daily | Sitagliptin 100 mg once daily | Metformin |